Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.


Journal

Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017

Informations de publication

Date de publication:
Sep 2020
Historique:
entrez: 16 8 2020
pubmed: 17 8 2020
medline: 8 6 2021
Statut: ppublish

Résumé

To explore the potentiality of radiomics analysis, performed on Ga-DOTATOC and fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) images, in predicting tumour aggressiveness and outcome in patients candidate to surgery for pancreatic neuroendocrine neoplasms (PanNENs). Retrospective study including 61 patients who underwent Ga-DOTATOC and F-FDG PET/CT before surgery for PanNEN. Semiquantitative variables [SUVmax and somatostatin receptor density (SRD) for Ga-DOTATOC PET; SUVmax and MTV for F-FDG PET] and texture features [intensity variability, size zone variability (SZV), zone percentage, entropy; homogeneity, dissimilarity and coefficient of variation (Co-V)] have been analysed to evaluate their possible role in predicting tumour characteristics. Principal component analysis (PCA) was firstly performed and then multiple regression analyses were performed by using the extracted principal components. Regarding Ga-DOTATOC PET, SZV, entropy, intensity variability and SRD were predictive for tumour dimension. Regarding F-FDG PET, intensity variability, SZV, homogeneity, SUVmax and MTV were predictive for tumour dimension. Four principal components were extracted from PCA: PC1 correlated with all F-FDG variables, while PC2, PC3 and PC4 with Ga-DOTATOC variables. PC1 was the only significantly predicting angioinvasion (P = 0.0222); PC4 was the only one significantly predicting lymph nodal involvement (P = 0.0151). All principal components except PC4 significantly predicted tumour dimension (P  <0.0001 for PC1, P = 0.0016 for PC2 and P < 0.0001 for PC3). Co-V from Ga-DOTATOC PET/CT was predictive of the outcome. Specific texture features derived from preoperative Ga-DOTATOC and F-FDG PET/CT could noninvasively predict specific tumour characteristics and patients' outcome, delineating the potential role of dual tracer technique and texture analysis in the risk assessment of patients with PanNENs.

Identifiants

pubmed: 32796478
doi: 10.1097/MNM.0000000000001236
pii: 00006231-202009000-00009
doi:

Substances chimiques

Ga(III)-DOTATOC 0
Organometallic Compounds 0
Radioactive Tracers 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
Octreotide RWM8CCW8GP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

896-905

Références

Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al.; all other Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449:395–401
Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011; 29:2372–2377
Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O’Connor JM, et al.; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012; 95:120–134
Partelli S, Gaujoux S, Boninsegna L, Cherif R, Crippa S, Couvelard A, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNENs). JAMA Surg. 2013; 148:932939
Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012; 56:40–47
Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009; 50:858–864
Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008; 112:2447–2455
Muffatti FPS, Cirocchi R, Andreasi V, Mapelli P, Picchio M, Gianolli L, Falconi M. Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). Clinical and Translational Imaging. 2019; 7:181–188
Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, Bellomi M. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp. 2018; 2:36
Ha S, Choi H, Paeng JC, Cheon GJ. Radiomics in oncological PET/CT: a methodological overview. Nucl Med Mol Imaging. 2019; 53:14–29
Cook GJR, Siddique M, Taylor BP, et al. Radiomics in PET: principles and applications. Clinical and Translational Imaging. 2014; 2:269–276
Hatt M, Tixier F, Pierce L, Kinahan PE, Le Rest CC, Visvikis D. Characterization of PET/CT images using texture analysis: the past, the present… any future? Eur J Nucl Med Mol Imaging. 2017; 44:151–165
Cheng NM, Fang YH, Lee LY, Chang JT, Tsan DL, Ng SH, et al. Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur J Nucl Med Mol Imaging. 2015; 42:419–428
Cook GJ, O’Brien ME, Siddique M, Chicklore S, Loi HY, Sharma B, et al. Non-small cell lung cancer treated with erlotinib: heterogeneity of (18)F-FDG uptake at pet-association with treatment response and prognosis. Radiology. 2015; 276:883–893
Hatt M, Majdoub M, Vallieres M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015; 56:38–44
Mapelli P, Salgarello M, Partelli S, Pasetto S, Rancoita PMV, Muffatti F, et al. Explorative texture analysis on dual tracer 68GADOTATOC and 18F-FDG PET/CT for preoperative risk evaluation in pancreatic neuroendocrine neoplasms. Clinical and Translasional Imaging. 2019; 7:S12
Presotto L, Bettinardi V, De Bernardi E, Belli ML, Cattaneo GM, Broggi S, Fiorino C. PET textural features stability and pattern discrimination power for radiomics analysis: An “ad-hoc” phantoms study. Phys Med. 2018; 50:66–74
Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, et al. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Clin Nucl Med. 2014; 39:e27–e34
Abdulrezzak U, Kurt YK, Kula M, Tutus A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun. 2016; 37:874–881
Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010; 51:353–359
Ambrosini V, Campana D, Polverari G, Peterle C, Diodato S, Ricci C, et al. Prognostic value of 68Ga-DOTANOC PET/CT SUVmax in patients with neuroendocrine tumors of the pancreas. J Nucl Med. 2015; 56:1843–1848
Hyun SH, Kim HS, Choi SH, Choi DW, Lee JK, Lee KH, et al. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2016; 43:1461–1468
Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Kitazono M, Yoshiura T. A pilot study for texture analysis of 18F-FDG and 18F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery. Eur J Nucl Med Mol Imaging. 2017; 44:2158–2168
Nakajo M, Jinguji M, Shinaji T, Aoki M, Tani A, Nakabeppu Y, et al. A Pilot study of texture analysis of primary tumor [(18)F]FDG uptake to predict recurrence in surgically treated patients with non-small cell lung cancer. Mol Imaging Biol. 2018; 21:771–780

Auteurs

Paola Mapelli (P)

Vita-Salute San Raffaele University.
Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute.

Stefano Partelli (S)

Vita-Salute San Raffaele University.
Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan.

Matteo Salgarello (M)

Department of Nuclear Medicine, IRCCS Sacro Cuore Don Calabria Hospital, Negrar.

Joniada Doraku (J)

Department of Nuclear Medicine, IRCCS Sacro Cuore Don Calabria Hospital, Negrar.

Stefano Pasetto (S)

Department of Nuclear Medicine, IRCCS Sacro Cuore Don Calabria Hospital, Negrar.

Paola M V Rancoita (PMV)

University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy.

Francesca Muffatti (F)

Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan.

Valentino Bettinardi (V)

Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute.

Luca Presotto (L)

Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute.

Valentina Andreasi (V)

Vita-Salute San Raffaele University.
Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan.

Luigi Gianolli (L)

Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute.

Maria Picchio (M)

Vita-Salute San Raffaele University.
Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute.

Massimo Falconi (M)

Vita-Salute San Raffaele University.
Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH